AAV9 has also recently demonstrated effectiveness in a mouse model of Canavan disease (Gessler et al., 2017), which played a role in promoting the rAAV9-ASPA vector transitioning to a recent open-label clinical trial for Canavan disease (CANaspire, ASPA Therapeutics). The gene discussed is ASPA; the disease is Canavan disease.